tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Beijing Chunlizhengda Reports Stable Interim Financial Results for 2025

Story Highlights
Beijing Chunlizhengda Reports Stable Interim Financial Results for 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest update is out from Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H ( (HK:1858) ).

Beijing Chunlizhengda Medical Instruments Co., Ltd. announced its unaudited consolidated interim results for the first half of 2025, showing a stable financial position with total assets amounting to RMB 3.49 billion as of June 30, 2025. The company’s current assets slightly increased, driven by a rise in held-for-trading financial assets, while its non-current assets also saw a modest increase, indicating ongoing investments in fixed assets and construction projects.

The most recent analyst rating on (HK:1858) stock is a Hold with a HK$18.00 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.

More about Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H

Beijing Chunlizhengda Medical Instruments Co., Ltd. is a joint stock limited company incorporated in China, operating in the medical instruments industry. The company focuses on the production and distribution of medical devices, with a specific emphasis on the Chinese market.

Average Trading Volume: 1,934,100

Technical Sentiment Signal: Buy

Current Market Cap: HK$8.29B

For detailed information about 1858 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1